Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company that develops and commercializes therapeutics and small molecule drugs for central nervous system (CNS), neuropsychiatric, and neurological disorders. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It distributes its products through third-party wholesale drug distributors. The company was founded in 2002 and is based in Bedminster, New Jersey. As of April 2, 2025, Intra-Cellular Therapies, Inc. operates as a subsidiary of Johnson & Johnson Innovative Medicine.
Market Dynamics | Learn about ITCI's commercial strategy, financial performance, and analyst perspectives, with price targets ranging from $132 to $135 pre-acquisition |
Pipeline Expansion | Discover ITCI's strategic pipeline developments, including long-acting injectables and new compounds, aimed at broadening its psychiatric treatment offerings |
CAPLYTA's Potential | Delve into CAPLYTA's market performance and its $5 billion potential as a first-choice treatment for mood disorders, driving ITCI's financial success |
J&J Acquisition | Explore how Johnson & Johnson's acquisition of Intra-Cellular Therapies reshapes the psychiatric drug landscape, potentially accelerating growth and market reach |